Across industries, companies are forging partnerships aimed at diagnosing and treating Covid-19. We highlight some of these initiatives and what this trend could mean for future emerging pathogens.
The US healthcare system is facing an increased need to quickly screen for, diagnose, and treat disease. Against the backdrop of the growing Covid-19 pandemic and initial testing kit delays, it has become clear that the system needs to better confront the virus and prepare for the next crisis.
In response, institutions across sectors — including biopharma, academia, hospitals, and technology — are establishing strategic alliances in order to develop testing and treatment solutions in a scalable way.
For example, tech giant Apple recently partnered with the CDC (Centers for Disease Control), White House, and FEMA (Federal Emergency Management Agency) to create a Covid-19 screening tool.
Partnerships are seeking to tackle the key issues posed by global pandemics from multiple angles, from creating more accessible testing kits to developing new drug therapies for severe symptoms.
Below, we take a look at some of these partnerships and how they could impact future responses to new pathogens.